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Little is known about the impact of comorbidity on cervical cancer survival in Australian
women, including whether Indigenous women’s higher prevalence of comorbidity contrib-
utes to their lower survival compared to non-Indigenous women.
Methods
Data for cervical cancers diagnosed in 2003–2012 were extracted from six Australian state-
based cancer registries and linked to hospital inpatient records to identify comorbidity diag-
noses. Five-year cause-specific and all-cause survival probabilities were estimated using
the Kaplan-Meier method. Flexible parametric models were used to estimate excess cause-
specific mortality by Charlson comorbidity index score (0,1,2+), for Indigenous women com-
pared to non-Indigenous women.
Results
Of 4,467 women, Indigenous women (4.4%) compared to non-Indigenous women had more
comorbidity at diagnosis (score1: 24.2% vs. 10.0%) and lower five-year cause-specific
survival (60.2% vs. 76.6%). Comorbidity was associated with increased cervical cancer
mortality for non-Indigenous women, but there was no evidence of such a relationship for
Indigenous women. There was an 18% reduction in the Indigenous: non-Indigenous hazard
ratio (excess mortality) when comorbidity was included in the model, yet this reduction was
not statistically significant. The excess mortality for Indigenous women was only evident
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among those without comorbidity (Indigenous: non-Indigenous HR 2.5, 95%CI 1.9–3.4),
indicating that factors other than those measured in this study are contributing to the differ-
ential. In a subgroup of New South Wales women, comorbidity was associated with
advanced-stage cancer, which in turn was associated with elevated cervical cancer
mortality.
Conclusions
Survival was lowest for women with comorbidity. However, there wasn’t a clear comorbidity-
survival gradient for Indigenous women. Further investigation of potential drivers of the cer-
vical cancer survival differentials is warranted.
Impact
The results highlight the need for cancer care guidelines and multidisciplinary care that can
meet the needs of complex patients. Also, primary and acute care services may need to pay
more attention to Indigenous Australian women who may not obviously need it (i.e. those
without comorbidity).
Introduction
Cancer patients commonly have comorbidities.[1, 2] There is evidence that higher comorbid-
ity burden is associated with worse survival for cancer patients.[3–5] The prevalence of comor-
bidity varies between population groups and may contribute to cancer survival disparities,
particularly for different ethnic groups.[6–11]
Evidence regarding the effect of comorbidity on survival for cervical cancer is limited and
inconsistent: comorbidity was not associated with higher mortality for Italian[12] or Mexican
[13] women with cervical cancer; it was associated with higher all-cause mortality but not can-
cer-specific mortality for women in the United States;[14, 15] and it was associated with both
all-cause and cancer-specific mortality for New Zealand (NZ) women.[11]
In Australia, cervical cancer incidence and mortality have fallen by approximately 50%
since the introduction of the National Cervical Screening Program in 1991.[16, 17] Five-year
survival also improved during the 1990s and has remained steady at about 72% since then.[18]
However, cervical cancer has a much greater impact on Aboriginal and Torres Strait Islander
women (respectfully referred to hereafter as Indigenous) than other Australian women; semi-
national and national analyses suggest Indigenous women are diagnosed younger (median age
46 vs. 52 years), incidence is 2.2 times higher, mortality 3.8 times higher and five-year survival
is 20 percentage points lower for Indigenous women (58% vs 78%).[18–20] In Queensland,
Indigenous women have lower cervical screening participation than non-Indigenous women
(two-year participation 34% vs 56% in 2010–2011)[21] and those who develop cervical cancer
are less likely to be diagnosed with localised disease (46% vs. 69%)[22] and receive cancer treat-
ment concordant with clinical guidelines (77% vs 96%).[23]
The prevalence of many chronic diseases including coronary heart disease, diabetes, kidney
disease and hypertension is higher for Indigenous Australians compared with other Austra-
lians[24] including for women with cervical cancer,[22] but the impact of comorbidity on cer-
vical cancer survival in Australia has not been examined for Australian women generally or
Indigenous women specifically. A NZ study found Māori and Pacific women diagnosed with
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cervical cancer had more chronic disease and excess cervical cancer mortality (i.e. lower sur-
vival) compared with other NZ women.[11] While adjusting for comorbidity as a summary
measure did not reduce the excess mortality, adjusting for 12 individual chronic conditions
appeared to reduce the excess by 21% for Māori and 35% for Pacific women.[11]
Our aims were to investigate whether: (1) comorbidity is associated with lower cervical can-
cer survival for Australian women generally; (2) higher comorbidity burden contributes to
lower survival for Indigenous women; (3) the effect of comorbidity on survival varies by type
of comorbid condition; and (4) comorbidity is associated with more advanced stage of disease
at diagnosis.
Methods
We linked cancer registry data for cases of cervical cancer (ICD-10 C53) with hospital inpa-
tient data to obtain comorbidity information. Data were available from six Australian states/
territories: New South Wales (NSW); Victoria (Vic); Queensland (Qld); South Australia (SA);
Western Australia (WA); and the Northern Territory (NT); together covering 96% of the total
Australian female population and 95% of the Indigenous female population.[25] Cases from
all jurisdictions entered the study in January or July 2003, except for those in Victoria who
entered the study in January 2007 because the Victorian Cancer Registry does not have ade-
quate cause of death data before 2007. To maximise the data available, cases were included if
they were diagnosed from study entry up until December 2007 (NSW), 2009 (Qld), 2010 (NT),
2011 (WA) and 2012 (Vic and SA). Cases were followed-up until December in the following
year (e.g. for NSW this was December 2008).
Cancer registry data included: Indigenous status; date of birth; place of residence (postcode
for Vic and WA, statistical local area for other jurisdictions); date of diagnosis; histological
type of cancer; date of death; cause of death; and, for NSW only, summary stage at diagnosis,
classified as localised, regional, distant metastases, or unknown/missing stage. Indigenous sta-
tus is not included in most pathology reports, which are the primary source of notifications to
cancer registries. Registries obtain Indigenous status from other notification sources including
hospital inpatient episodes, radiotherapy clinics, death notifications, active follow-up with
treating doctors, and other secondary sources. The national standard Indigenous identification
question asks whether the person identifies as: Aboriginal; Torres Strait Islander; both; or nei-
ther. For most Australian states, Indigenous identification in hospital data is considered to be
of high-quality. Nationally, 88% of Indigenous patients were estimated to be correctly identi-
fied in Australian public hospitals in 2011–12. For states included in this study, accuracy ran-
ged from 78% in Victoria to 98% in the Northern Territory during this time[26]
Death data were not available for cases who had died outside of Australia and it is unknown
how many cases are missed due to this. Ascertainment of deaths by the cancer registries was
complete for deaths occurring up to the end of the follow-up period in each jurisdiction. Most
registries provided only month and year for date of birth, diagnosis and death, so the 15th of
the month was used to calculate survival time and age at diagnosis for all cases. Survival time
was calculated as the number of months from diagnosis to death or the end of follow-up.
Cause of death was classified as cervical cancer or other. Histological type of cancer was
grouped as: squamous cell carcinoma; adenocarcinoma; adenosquamous carcinoma; and
other carcinoma or sarcoma.[16] Mapping to place of residence was done using the Statistical
Local Area (SLA) definitions of the 2006 Australian Geographical Classifications (ASGC)[27]
or using postcode information (for Vic and WA). SLA or postcode of residence was mapped
to the Socio-economic Index for Areas (SEIFA) 2006 Index of Relative Socioeconomic Advan-
tage and Disadvantage (IRSAD) and divided into five quintiles (‘most advantaged’ to ‘most
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disadvantaged’),[28] and to the Accessibility/Remoteness Index for Australia (ARIA) 2006 and
classified into five remoteness categories (‘major city’ to ‘very remote’).[29]
Record linkage
In each jurisdiction, the data custodians of the cancer registry and hospital inpatient dataset
provided identifying information (name, date of birth, place of residence) to their local data
linkage unit (DLU) or Health Department who performed the matching and returned project-
specific linkage keys to the custodians. The custodians then provided de-identified clinical
datasets to the research team who merged the two datasets using the linkage keys. Each juris-
diction’s linked data was then combined into the semi-national dataset for analysis. The link-
age process for Queensland has been described in detail previously.[30] Three states (NSW,
Vic, WA) provided data for both private hospital and public hospital admissions and three
jurisdictions (Qld, SA, NT) provided data for public hospital admissions only.
Eligibility criteria
For each woman, the first eligible cervical cancer diagnosis within the study period was
included. Women were excluded if they were diagnosed: with a micro-invasive cervical cancer;
on the basis of death certificate only, autopsy only, or basis unknown; younger than age 22
years (to allow for sufficient measurement of baseline comorbidity); or older than 89 years
(because assignation of cause of death is less reliable for this age-group[31, 32]). In Queens-
land, cervical cancer diagnoses were provided for women aged up to 69 years only.
Indigenous status
Women were classified as Indigenous if they were recorded as Indigenous (Aboriginal and/or
Torres Strait Islander) in the cancer registry or in at least half of their linked inpatient admis-
sions during the entire study period (as per an algorithm we have used previously[30]).
Comorbidity
Comorbidity at the time of cancer diagnosis was measured using both the Charlson Comor-
bidity Index (CCI)[33] and the Elixhauser index.[34] Inpatient episodes with an admission
date up to 730 days (two years) prior to, and including, the date of cancer diagnosis were
searched for primary and secondary diagnosis (ICD) codes for the conditions included in each
of the indices (excluding gynaecological cancers), using validated coding algorithms.[35] For
each woman, binary indicators were created for each condition (present/absent), which were
used to calculate the Charlson score (a weighted sum of the number of conditions present[33])
and the Elixhauser score (an unweighted count of the number of conditions present[11]). The
measures were then categorised as score ‘0’ (no known comorbidity), ‘1’ and ‘2+’, with higher
scores indicating higher comorbidity burden.
Analysis
The difference in median age at diagnosis (which was positively skewed) for Indigenous and
non-Indigenous women was tested using the Mann-Whitney U-test. Other clinical and demo-
graphic characteristics of Indigenous and non-Indigenous women were described using fre-
quency distributions and compared using the Pearson’s chi-squared test. Cause-specific and
all-cause survival were estimated by unadjusted Kaplan-Meier survival probabilities, stratified
by comorbidity score, Indigenous status, and age group.
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Multivariable regression analysis of five-year cause-specific and all-cause mortality was per-
formed using flexible parametric models. Using the Bayesian Information Criterion, four
knots (three degrees of freedom), placed at default locations of survival time, were determined
to provide the best fit to model the baseline hazard function. The effect of comorbidity on sur-
vival varied by month after diagnosis (p<0.01). This meant that the conventional Cox propor-
tional hazards regression could not be used as the assumption of proportionality was violated.
A term was added to the flexible parametric model to account for the time-dependent effect of
comorbidity. The main effects model included variables: Charlson score (0,1,2+); Indigenous
status; age at diagnosis (in years); quintiles of area-level socioeconomic advantage and disad-
vantage; and cervical cancer histology type. The associations with diagnosis period, state/terri-
tory and place of residence were found to be small and not statistically significant (likelihood-
ratio chi-squared test p>0.1), so these variables were not included in the model. The associa-
tion between comorbidity and the survival differential between Indigenous and non-Indige-
nous women was initially assessed by comparing the hazard ratio from models with and
without comorbidity and examining whether the corresponding confidence intervals over-
lapped. Likelihood ratio chi-squared tests were used to assess if one model was a better fit than
another. Interactions between comorbidity and all confounders and Indigenous status and all
confounders were examined during model development and inclusion was based on effect size
and statistical significance (Wald test p<0.01). Interaction terms for comorbidity by Indige-
nous status and comorbidity by age at diagnosis were subsequently included in the final
model, along with the variables included in the main effects model.
The main effects model and the final model with interactions were fitted using different
measures of comorbidity: (1) the Elixhauser score; (2) indicator variables for each comorbid
condition, one at a time; (3) all Charlson indicator variables found to be associated with mor-
tality in the previous models (HR>1.5; a previously used cut-point[11]); and (4) all Elixhauser
indicator variables found to be associated with mortality (HR>1.5).
Relative survival
Relative survival requires population denominator data (life tables). Life tables stratified by
comorbidity level are not available and life tables stratified by Indigenous status are only avail-
able for limited years. We used cause-specific survival, but this method relies on accurate cause
of death data to distinguish deaths caused by cervical cancer from deaths due to other causes.
To support the use of this method, we compared cause-specific with relative survival for Indig-
enous and non-Indigenous women diagnosed during 2006–2010, without adjusting for
comorbidity level.
Sensitivity analyses
This study assumed women with cervical cancer who did not link to a hospital record had no
comorbidity. Sensitivity analyses were performed to compare the general patterns of survival
and mortality when women who did not link to a hospital record (over the entire period for
which data was provided) were included and excluded from the analysis. This was done using
Kaplan-Meier survival estimates and flexible parametric survival models, as described above.
Sub-group analysis for stage of cancer
For NSW cases (24% of total cases), logistic regression was used to assess associations between
stage at diagnosis and Charlson score and Indigenous status, separately. Multivariable flexible
parametric survival models were used to assess the association between Charlson score and
cause-specific mortality, comparing models excluding and including stage at diagnosis, and
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adjusted for age at diagnosis and Indigenous status. Finally, an interaction term for comorbid-
ity and cancer stage was included in this model to predict and graph five-year survival for
women with and without comorbidity, stratified by stage at diagnosis.
All analyses were conducted in Stata 14 (StataCorp, College Station, Texas, USA). For flexi-
ble parametric survival models, the stpm2 package of commands was used.
Ethics and approvals
The study was approved by 13 Human Research Ethics Committees (HRECs), including spe-
cialist Indigenous HRECs, as well as data custodians and data linkage units in each participat-
ing jurisdiction. Anonymised data was provided only, which meant it was not possible to
contact women for consent and the requirement of individual consent was waived by the eth-
ics committees.
Results
Of 4,467 women eligible for inclusion, Indigenous women were: younger at diagnosis; more
likely to live in remote areas and areas of socio-economic disadvantage; and less likely to be
diagnosed with an adenocarcinoma (Table 1). Prevalence of any comorbidity was higher for
Indigenous than non-Indigenous women (Charlson: 24.2% vs. 10.0%; Elixhauser: 45.4% vs
16.6%, respectively) (Table 2). The most common conditions for Indigenous women included:
excessive alcohol use (13%); uncomplicated hypertension (11%); fluid and electrolyte disorders
(9.1%); complicated (8%) and uncomplicated diabetes (7%); deficiency anaemia (6%); serious
kidney disease (6%); and chronic respiratory disease (6%) (Table 2 and S1 Table). While more
comorbidities were identified using the Elixhauser score, the association between comorbidity
and cause-specificr survival was similar regardless of which comorbidity measure was used
(see S1–S5 Tables). Charlson comorbidity score is reported hereafter, unless stated otherwise.
Cause-specific mortality
1,171 women died within five years of diagnosis; 82.0% died from cervical cancer. For all
women combined, five-year cause-specific survival was 75.8% (Table 3). Five-year survival
decreased with increasing levels of comorbidity for non-Indigenous women, yet for Indige-
nous women survival was similar for those with a Charlson score of 0 or 1 but much lower for
those with a score of 2+.
In multivariable analysis, without interaction terms, the age-adjusted risk of dying was 2.6
times higher for Indigenous than non-Indigenous women (HR 2.6, 95%CI 2.0–3.3; S6 Table).
The hazard ratio reduced when adjusted for histology type and socioeconomic status (HR 2.2,
1.7–2.8; LR test p<0.001 compared to the previous model), and reduced further when adjusted
for comorbidity score (HR 1.8, 1.4–2.3; LR test p<0.001). Ten of the Charlson conditions had
HRs>1.5 in separate models (S7 Table), but adjustment for each of these individual condi-
tions (rather than the summary Charlson score) resulted in a similar adjusted Indigenous:
non-Indigenous hazard ratio (HR 2.0, 1.5–2.6, LR test P<0.001).
However, the relationship between comorbidity and survival differed for Indigenous and
non-Indigenous women and by age at diagnosis. When interaction terms were added to the
multivariable model, mortality increased significantly with increasing comorbidity only for
non-Indigenous women (Table 4). For Indigenous women, these differences were not statisti-
cally significant (Table 4). These patterns meant the mortality differential for Indigenous and
non-Indigenous women was only evident for those without comorbidity (Fig 1). Increasing
age at diagnosis was strongly associated with higher mortality for women without comorbidity
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Table 1. Demographic and clinical characteristics of 4,467 Australian women diagnosed with cervical cancer 2003–2012, by Indigenous status.
Indigenous Non-Indigenous Pa
TOTAL n(%) 198(4.4) 4,269 (95.6)
Age in years (median, IQR) 41.6 (35.2, 51.1) 47.0 (36.8, 61.4) <0.001
Age group % %
22–39 years 44.4 32.8 <0.001
40–49 years 28.3 23.9
50–59 years 16.2 17.6
60–69 years 7.1 12.8
70–79 years 3.5 6.7
80–89 years 0.5 6.1
State/territoryb
New South Wales 20.7 24.1 <0.001
Victoria 8.1 24.8
Queensland 27.8 20.9
South Australia 2.5 11.2
Western Australia 26.8 17.9
Northern Territory 14.1 1.1
Area-level socioeconomic disadvantage quintile (Q)




Most disadvantaged (Q1) 32.3 11.4
Missing 3.5 0.8
Place of residence
Major city 25.3 72.6 <0.001
Inner regional 17.2 16.4
Outer regional 24.8 8.6
Remote 14.7 1.4
Very remote 15.7 0.2
Missing 2.5 0.8
Histological type of cervical cancer
Squamous cell carcinoma 78.3 65.2 <0.001
Adenocarcinoma 10.1 23.9
Adeno-squamous carcinoma 2.0 3.1
Other carcinoma or sarcoma 9.6 7.8
Stage of cancer at diagnosis,
For 1,069 NSWwomen only
41 women 1,028 women
Localised 41.5 47.2 0.09
Regional spread 34.2 27.8
Distant metastases 17.1 8.3
Unknown 7.3 16.7
Abbreviations: IQR: Interquartile range; Q: Quintile; NSW: New South Wales; P: p-value
NOTES:
a. Mann-Whitney U-test was used to test differences between medians; Chi-squared test was used to test differences in proportions.
b. In all jurisdictions, except Queensland, data were provided for women diagnosed with cervical cancer aged 22–89 years. In Queensland, data were provided for
women up to age 69 years only.
https://doi.org/10.1371/journal.pone.0196764.t001
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(4% increase in mortality per year of age), but the association was smaller for women with
comorbidity score of 1 or 2+ (and confidence intervals bordered 1.0) (Table 4).
All-cause mortality
All-cause survival followed similar patterns to cause-specific survival (Table 3) and mortality:
higher comorbidity score was associated with higher mortality, more so for non-Indigenous
than Indigenous women; excess mortality for Indigenous compared with non-Indigenous
women was evident only for women without comorbidity; and mortality increased with
increasing age, for women without comorbidity or score of 1, but not for women with a
comorbidity score of 2+.
Sensitivity analysis
Overall, 12.5% of women in the cohort did not link to any hospital record (Indigenous 2.0%;
non-Indigenous 12.9%). Failure to link was less common for women from jurisdictions with










Acute myocardial infarction 1.5 0.6 0.14
Congestive heart failure 4.0 0.9 <0.001
Peripheral vascular disease 0.5 0.5 0.94
Cerebrovascular disease 1.5 0.5 0.07
Dementia 0.0 0.5 0.31
Chronic pulmonary disease 5.6 1.8 <0.001
Connective tissue disease 0.5 0.4 0.77
Peptic ulcer disease 0.0 0.1 0.60
Mild liver disease 2.5 0.7 0.003
Diabetes without complications 6.6 1.7 <0.001
Diabetes with complications 7.6 2.3 <0.001
Paraplegia 1.0 0.3 0.12
Moderate-severe kidney disease 5.6 1.7 <0.001
Invasive cancer, excl. gynaecological 3.5 1.6 0.04
Moderate-severe liver disease 0.5 0.2 0.27
Metastatic cancer, excl. gynaecological 3.0 1.5 0.10
AIDS 0.0 0.0
Charlson scoreb <0.001






a. Chi-squared test was used to test differences in proportions.
b. Comorbidity was measured using diagnoses codes contained in hospital admissions data for the two years prior to and including the woman’s cervical cancer
diagnosis date.
c. No known comorbidity includes women who linked to hospital records and did not have comorbidity and women who did not link to a hospital record and have
unknown comorbidity.
https://doi.org/10.1371/journal.pone.0196764.t002
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private hospital data (5.8%) than without (25.5%), and less common with increasing socioeco-
nomic disadvantage, more so in the jurisdictions without private hospital data (least disadvan-
taged areas 28%, most disadvantaged areas 6%) than in those with private hospital data (7.7%,
4.4%). Women in the jurisdictions with private hospital data had similar comorbidity as those
in the jurisdictions without private hospital data (11% vs. 10%). Cause-specific mortality fol-
lowed similar patterns regardless of whether women who did not link to any hospitalisation
were included in the analysis (and assumed to have no comorbidity) or excluded.
Table 3. Crude five-year Kaplan-Meier survival estimates for 4,467 Australian women (22–89 years)a diagnosed with cervical cancer, 2003–2012, stratified by Charl-
son comorbidity score (0,1,2+).
Five-year cause-specific survival (%, 95%CI)
All women Charlson comorbidity score b
0 1 2+
All women 75.8 (74.4–77.2) 79.0 (77.6–80.3) 67.4 (58.6–74.7) 36.6 (30.2–43.1)
Indigenous status
non-Indigenous 76.6 (75.1–77.9) 79.6 (78.1–80.9) 66.9 (57.6–74.6) 37.3 (30.4–44.1)
Indigenous 60.2 (52.4–67.0) 64.8 (56.1–72.2) 72.0 (41.2–88.6) 32.2 (14.7–51.1)
Age group
22–39 years 88.9 (87.0–90.5) 89.6 (87.7–91.1) 82.4 (54.7–93.9) 41.9 (18.3–64.1)
40–49 years 81.3 (78.5–83.7) 83.1 (80.3–85.5) 66.8 (46.1–81.0) 47.8 (30.8–62.9)
50–59 years 70.2 (66.5–73.6) 73.0 (69.2–76.5) 81.3 (63.0–91.1) 32.5 (17.5–48.5)
60–69 years 63.4 (58.8–67.6) 67.3 (62.5–71.8) 59.4 (35.8–76.8) 33.8 (21.0–47.0)
70–79 years 57.9 (51.3–64.0) 61.2 (53.3–68.1) 55.6 (32.2–73.8) 46.9 (31.9–60.5)
80–89 years 38.2 (31.1–45.3) 42.1 (33.6–50.3) 60.1 (35.7–77.8) 14.8 (4.0–32.1)
Diagnosis period
2003–2007 75.6 (73.8–77.3) 79.1 (77.3–80.8) 64.9 (54.2–73.7) 37.1 (29.3–44.9)
2008–2012 76.3 (73.8–78.6) 78.9 (76.4–81.2) 73.1 (56.7–84.1) 36.9 (26.2–47.7)
Five-year all-cause survival (%, 95%CI)
All women Charlson comorbidity score b
0 1 2+
All women 70.8 (69.4–72.3) 75.3 (-73.8–76.8) 52.3 (43.6–60.3) 24.3 (19.3–29.7)
Indigenous status
non-Indigenous 71.7 (70.2–73.1) 75.9 (74.4–77.3) 52.3 (43.0–60.7) 24.9 (19.5–30.6)
Indigenous 53.4 (45.8–60.4) 61.0 (52.2–68.6) 52.5 (25.2–74.0) 20.2 (8.0–36.4)
Age group a
youngest-39 years 87.6 (85.7–89.3) 88.3 (86.4–90.0) 82.4 (54.7–93.9) 39.5 (17.2–62.2)
40–49 years 78.3 (75.4–80.9) 80.5 (77.6–83.1) 59.9 (39.5–75.4) 42.2 (26.8–56.8)
50–59 years 65.7 (61.9–69.2) 70.2 (66.2–73.8) 66.6 (46.4–80.6) 22.9 (11.9–36.1)
60–69 years 57.6 (53.1–61.9) 62.8 (57.8–67.4) 41.6 (20.7–61.3) 25.4 (14.9–37.2)
70–79 years 44.9 (38.7–50.9) 50.6 (43.0–57.7) 48.2 (26.6–66.8) 24.5 (14.2–36.3)
80–89 years 21.3 (16.1–27.0) 27.1 (20.3–34.3) 19.8 (6.3–38.6) 3.2 (0.3–12.2)
Diagnosis period
2003–2007 70.3 (68.4–72.1) 75.5 (73.6–77.2) 49.2 (39.0–58.7) 23.3 (17.5–29.6)
2008–2012 72.1 (69.5–74.5) 75.3 (72.7–77.8) 61.6 (45.8–74.1) 28.6 (19.4–38.4)
Abbreviations: CI: Confidence Interval
Notes:
a. All jurisdictions provided data for women aged 22–89 years at diagnosis of cervical cancer, with the exception of Queensland, which only provided data for women
aged 22–69 years at diagnosis.
b. No known comorbidity (0) includes women who linked to hospital records and did not have comorbidity and women who did not link to a hospital record and have
unknown comorbidity.
https://doi.org/10.1371/journal.pone.0196764.t003
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Stage at diagnosis
Almost half of NSW women (47.0%) were diagnosed with localised cancer (16.4% had
unknown or missing stage). The odds of advanced-stage diagnosis were greater for Indigenous
than non-Indigenous women (OR 1.9, 95%CI 0.99–3.5) and for women with comorbidity
(score 1: OR 3.0, 1.8–5.1; score 2+: OR 2.1, 1.4–3.2) than those without. In the multivariable
analysis (adjusted for Indigenous status, age at diagnosis, histology type, and socioeconomic
status) cause-specific mortality was higher for women with than without comorbidity (score 1:
HR 1.7, 1.1–2.7; 2+: HR 1.8, 1.3–2.6), but these associations were attenuated and became not
statistically significant when also adjusted for stage at diagnosis (score 1: HR 1.3, 0.8–2.0; 2+:
Table 4. Adjusted hazard ratios for five-year cause-specific mortality for Australian women, 22–89 years, diag-
nosed with cervical cancer, 2003–2012 a, b.
Adjusted HR c 95%CI
Charlson comorbidity score Chi-sq = 15.8, df = 2, p<0.001e
Indigenous women




0 (No known comorbidity) d 1.00
1 1.72 (1.10–2.68)
2+ 4.62 (3.54–6.03)
Age at diagnosis, per year increase Chi-sq = 24.46, df = 2, p<0.001e
Charlson score 0 d 1.04 (1.04–1.04)
Charlson score 1 1.02 (1.01–1.04)
Charlson score 2+ 1.01 (1.00f-1.02)
Area level socioeconomic disadvantage Chi-sq = 24.9, df = 5, p<0.001g




Most disadvantaged (Q1) 1.51 (1.20–1.89)
Missing 0.79 (0.40–1.57)
Histology type Chi-sq = 75.4, df = 3, p<0.001g
Squamous cell carcinoma 1.00
Adenocarcinoma 0.77 (0.65–0.92)
Adenosquamous carcinoma 1.24 (0.87–1.76)
Other carcinoma or sarcoma 2.19 (1.81–2.64)
Abbreviations: HR: hazard ratio; CI: confidence interval; Q: quintile.
Notes:
a. All jurisdictions entered the study in 2003, except for Victoria which entered the study in 2007. Jurisdictions exited
the study in 2007 (NSW), 2009 (QLD), 2010 (NT), 2011 (WA), and 2012 (VIC and SA).
b. All jurisdictions contributed women aged 22–89 years at diagnoses, except for Queensland which contributed
women aged 22–69 years only.
c. Hazard ratios were mutually adjusted for all variables and interactions listed in this table
d. No known comorbidity includes women who linked to hospital records and did not have comorbidity and women
who did not link to a hospital record (unknown comorbidity)
e. Significance of interaction terms based on likelihood ratio tests
f. p = 0.9998
g. Significance of main effect based on likelihood ratio test
https://doi.org/10.1371/journal.pone.0196764.t004
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HR 1.2, 0.9–1.8). Stratified survival curves show that comorbidity is associated with lower sur-
vival only for women with localised disease (and for women with unknown stage), but not for
women with regional or distant spread (Fig 2).
Discussion
We have shown that increased comorbidity is associated with reduced five-year cause-specific
and all-cause survival for Australian women diagnosed with cervical cancer. This finding is
consistent with previous findings from New Zealand,[11] a neighbouring country with similar
culture, healthcare system and cervical screening program,[36, 37] but is not consistent with
findings reported from other countries.[12, 13] Elsewhere and for other cancer types, it has
been well established that comorbidity is associated with higher mortality from any cause, but
it is less clear if comorbidity is associated with cancer-specific death.[2] One explanation for
our results is that comorbidity may form a barrier to participation in cancer screening,[38]
which may lead to more advanced disease at diagnosis.[39] Comorbidity may also limit
Fig 1. Cause-specific mortality rates for Indigenous and non-Indigenous women stratified by Charlson Comorbidity Index score, adjusted
for age at diagnosis, area-level socioeconomic status, and histology type.
https://doi.org/10.1371/journal.pone.0196764.g001
Fig 2. Cause-specific survival for NSW women (n = 1,069) by Charlson Comorbidity Index score, stratified by cancer stage, adjusted for age
at diagnosis and Indigenous status.
https://doi.org/10.1371/journal.pone.0196764.g002
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treatment options and increase the risk of treatment complications.[1] We were unable to
assess screening participation and treatment in this study. However, for NSW women, we
were able to demonstrate that comorbidity is associated with more advanced disease at diagno-
sis, which is suggestive of lower screening participation by these women.
Surprisingly, the pattern of increasing mortality with increasing comorbidity was only
observed for non-Indigenous women. For Indigenous women, the relationship between
comorbidity and mortality was less definitive. While this is in part due to the small numbers of
Indigenous women, which leads to low precision and power, the results suggest a much
weaker, if any, association between comorbidity and cervical cancer mortality for Indigenous
women. Adjustment for comorbidity, particularly as a summary measure rather than individ-
ual conditions, did reduce the Indigenous: non-Indigenous hazard ratio somewhat: 18% with
the Charlson summary score and 9% with individual Charlson conditions. A similar pattern
was observed when the Elixhauser score was used. However, these reductions were not statisti-
cally significant (as indicated by overlapping confidence intervals) and there still remained
substantial excess mortality for Indigenous women compared to non-Indigenous women after
adjustment.
Indigenous women with comorbidity score 2+ only had slightly higher mortality than
Indigenous women without comorbidity and survival was highest for Indigenous women with
a comorbidity score of 1. In Queensland, most Indigenous women do not participate in cervi-
cal screening, but those who do screen tend to do so regularly.[21] It is plausible that these are
the women with mild comorbidity, who may have greater contact with the healthcare system
and thus may be more likely to receive opportunistic screening or an earlier diagnosis of symp-
tomatic disease.
Differences in treatment receipt for Indigenous and non-Indigenous women may also
explain this finding. For NSW non-small cell lung cancer patients, Indigenous patients without
comorbidity were half as likely to receive surgery as non-Indigenous patients, while there was
no difference in surgery rates for Indigenous and non-Indigenous patients with comorbidity.
[40] Although it is not clear whether these patterns are generalizable to cervical cancer treat-
ment, the combination of lower participation in cervical screening,[21] more advanced disease
at diagnosis,[22, 41, 42] and less optimal cancer treatment[23] is likely to at least partially
explain the survival differential for Indigenous women compared to non-Indigenous women.
That this relationship is restricted to women without comorbidity suggests factors other than
those measured in this study are responsible for most of the survival differential and this war-
rants further investigation.
Australia has transitioned its National Cervical Screening Program from two-yearly Pap
testing to the more effective Human Papillomavirus screening test with a longer screening
interval of five years.[16] It is not clear what effect this change will have on screening participa-
tion. The longer interval may improve screening participation because it is less of a burden on
women, or alternatively participation may fall because infrequency leads to disengagement
with the program, particularly for women without comorbidity who have less reason to inter-
act with the healthcare system. The new program will also provide an option of in-clinic self-
collected screening (a vaginal swab) for hard-to-reach and under-screened women.[16] While
this is a valuable option, if comorbidity prevents women from attending a medical centre in
the first place, it may have little impact on screening participation and cervical cancer out-
comes for these women. Understanding how comorbidity influences women’s participation in
the screening program may provide valuable insight as to whether outreach services are
required (e.g. self-sampling in the home setting under the supervision of a health care worker).
Geographical remoteness and socioeconomic disadvantage could impact mortality by limit-
ing access to preventive (e.g. screening) or treatment services. In our study, living in higher
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socioeconomic areas was associated with higher survival, similar to that observed in previous
studies,[43, 44] and Indigenous women living in areas of greater disadvantage accounted for
some of the Indigenous: non-Indigenous survival differential. In contrast with previous find-
ings,[19, 45] place of residence was not associated with excess mortality after adjustment for
other factors. Survival inequalities previously reported for women in remote areas may partly
reflect the higher proportion of Indigenous people and socioeconomic disadvantage in these
areas.[44, 46]
Strengths and limitations
The relationship of increasing mortality with increasing comorbidity is clear for non-Indige-
nous women. However, for Indigenous women the small numbers in some groups, especially
the group with comorbidity score of 1, meant the confidence intervals were wide and findings
imprecise. Our findings do not provide strong evidence that there is no association between
comorbidity and excess mortality for Indigenous women, but our findings do indicate that if
there is such an association for Indigenous women, it is considerably smaller than for non-
Indigenous women. The larger numbers of women with no comorbidity provide strength to
our finding of an important Indigenous: non-Indigenous survival differential among women
without comorbidity. This finding suggests that factors other than comorbidity are responsible
for the disparity in cervical cancer survival between Indigenous and other Australian women.
This study examined the relationship between individual comorbid conditions and cause-spe-
cific survival for the whole cohort of women, but the small number of Indigenous women
meant this could not be explored separately for them. For the same reason, the experience of
Torres Strait Islander women could not be investigated separately from that of Aboriginal
women.
A major limitation of this study was the lack of information on women’s cervical screening,
cancer treatment, and stage of cancer at diagnosis. Cancer stage is a powerful predictor of sur-
vival and thus its absence from cancer registries limits evaluation of cancer programs, the
effective allocation of resources, and the ability to accurately compare cancer outcomes across
population groups.[47] In Australia, stage at diagnosis is only routinely collected by one regis-
try, however a previous validation study found that the routine collection of staging informa-
tion by cancer registries would be feasible for most cancer types;[47] we urge them to do so.
This study relies on: (1) the ability of the comorbidity tool to capture all important comor-
bidity for women with cervical cancer; (2) the accuracy and completeness of hospitals’ coded
diagnosis data; and (3) accurate record linkage. We utilised two measures of comorbidity, and
while the Elixhauser (which includes a greater number of conditions) identified more comor-
bidity, the patterns of association between comorbidity and mortality were similar for the two
measures. Neither the Charlson nor the Elixhauser indices were developed or have been vali-
dated for Indigenous people with cancer, despite their common use for this population group
in Australia. Given the different characteristics of Indigenous women compared to non-Indig-
enous women (e.g. more likely to be diagnosed at a younger age and with advanced-stage dis-
ease) it is possible that neither of these indices capture the most important comorbidities for
this population. Development and use of an Indigenous-specific comorbidity index may find
an association between comorbidity and excess mortality that was not apparent in this study.
We limited our definition of comorbidity to conditions recorded in inpatient records for the
two years prior to cervical cancer diagnosis. This means that included conditions may have
been diagnosed at any time in the past. While a longer lookback period may ascertain more
comorbid conditions, previous studies suggest a longer lookback is unlikely to alter the rela-
tionship between comorbidity and mortality.[11, 48, 49]
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It is likely that we did not identify all comorbid conditions, particularly conditions that are
managed in primary care and do not warrant hospitalisation. A Canadian study demonstrated
that more comorbidity was identified for hypertensive patients using hospital and health insur-
ance data than hospital data alone (even with a longer lookback period).[50] However, while
multiple data sources were found to produce a comorbidity measure that better predicted one-
year mortality, the relationship between comorbidity and mortality was similar regardless of
the data sources used.
Women were more likely to link to a hospital record in the jurisdictions that provided both
public and private hospital data. Even when assuming those who did not link had no comor-
bidity, the proportion of women with comorbidity was similar in jurisdictions with and with-
out private hospital data. Other reasons for non-linkage may include a failure of the linkage
process through false negative matches, non-linkage of women who were hospitalised inter-
state, or true non-matches for women who had not been hospitalised. It is unknown to what
degree and in which direction the lack of linkage may have biased the association between
comorbidity and survival, although the sensitivity analysis suggests it had little impact.
Our comparison of cause-specific and relative survival for Indigenous and non-Indigenous
women (not stratified by comorbidity level) found that the cause-specific method may under-
estimate five-year survival by up to 2% in comparison to relative survival. Previous research
has shown that use of cause-specific and relative survival produced similar estimates for Indig-
enous and non-Indigenous Australians with cancer.[20] The accurate attribution of cause of
death may be more difficult for cancer patients who also have other chronic conditions,
including other cancers, but we have no evidence as to the direction or magnitude of this
potential bias. We did not conduct a competing risks analysis for this cohort, which provides a
measure of cancer mortality, taking non-cancer deaths (competing risks) into account. There
is evidence that relative survival, cause-specific survival, and competing risks analysis similarly
highlight the excess cancer mortality burden faced by Indigenous cancer patients compared
with non-Indigenous patients.[51]
Conclusion
Comorbidity is an important prognostic factor for Australian women diagnosed with cervical
cancer, and further research (which preferably utilises multiple public health datasets to mea-
sure comorbidity) should investigate the underlying mechanisms of this relationship. Comor-
bidity contributed little, if any, to the lower survival for Indigenous women. There was a large
survival disparity observed among those without comorbidity. Plausibly, these women have
less interaction with the healthcare system and are thus less engaged with cancer screening
programs and/or treatment services, and there is a role here for primary care providers to
devise ways in which Indigenous women who are relatively healthy are engaged with these ser-
vices and programs.
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